S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:ALNY

Alnylam Pharmaceuticals Competitors

$125.45
-0.21 (-0.17 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$123.68
Now: $125.45
$128.00
50-Day Range
$122.97
MA: $133.82
$147.00
52-Week Range
$84.97
Now: $125.45
$167.33
Volume512,765 shs
Average Volume690,973 shs
Market Capitalization$14.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.59

Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying ALNY stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Alnylam Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Amgen has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Profitability

This table compares Amgen and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Institutional and Insider Ownership

71.7% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Amgen and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.49$7.84 billion$14.8214.87
Alnylam Pharmaceuticals$219.75 million66.32$-886,120,000.00($8.11)-15.47

Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Amgen and Alnylam Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Alnylam Pharmaceuticals161302.60

Amgen currently has a consensus target price of $254.08, indicating a potential upside of 15.33%. Alnylam Pharmaceuticals has a consensus target price of $153.00, indicating a potential upside of 21.96%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Amgen.

Summary

Amgen beats Alnylam Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Gilead Sciences has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Gilead Sciences and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.32$5.39 billion$6.149.69
Alnylam Pharmaceuticals$219.75 million66.32$-886,120,000.00($8.11)-15.47

Gilead Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Gilead Sciences and Alnylam Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
Alnylam Pharmaceuticals161302.60

Gilead Sciences currently has a consensus target price of $76.1538, indicating a potential upside of 27.99%. Alnylam Pharmaceuticals has a consensus target price of $153.00, indicating a potential upside of 21.96%. Given Gilead Sciences' higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than Alnylam Pharmaceuticals.

Summary

Gilead Sciences beats Alnylam Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Vertex Pharmaceuticals and Alnylam Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals082212.77
Alnylam Pharmaceuticals161302.60

Vertex Pharmaceuticals currently has a consensus target price of $290.5862, indicating a potential upside of 33.24%. Alnylam Pharmaceuticals has a consensus target price of $153.00, indicating a potential upside of 21.96%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.62$1.18 billion$4.2950.84
Alnylam Pharmaceuticals$219.75 million66.32$-886,120,000.00($8.11)-15.47

Vertex Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Alnylam Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alnylam Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals161302.60
Regeneron Pharmaceuticals0101312.63

Alnylam Pharmaceuticals currently has a consensus target price of $153.00, indicating a potential upside of 21.96%. Regeneron Pharmaceuticals has a consensus target price of $628.52, indicating a potential upside of 23.65%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Alnylam Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
Regeneron Pharmaceuticals37.30%26.71%19.39%

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million66.32$-886,120,000.00($8.11)-15.47
Regeneron Pharmaceuticals$7.86 billion6.90$2.12 billion$21.4723.68

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Alnylam Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alnylam Pharmaceuticals and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals161302.60
Biogen5151302.24

Alnylam Pharmaceuticals currently has a consensus target price of $153.00, indicating a potential upside of 21.96%. Biogen has a consensus target price of $305.9032, indicating a potential upside of 26.54%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Alnylam Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
Biogen35.63%51.00%23.54%

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million66.32$-886,120,000.00($8.11)-15.47
Biogen$14.38 billion2.59$5.89 billion$33.577.20

Biogen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.9% of Biogen shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Biogen beats Alnylam Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alnylam Pharmaceuticals and Seagen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals161302.60
Seagen161112.63

Alnylam Pharmaceuticals currently has a consensus target price of $153.00, indicating a potential upside of 21.96%. Seagen has a consensus target price of $176.75, indicating a potential upside of 6.83%. Given Alnylam Pharmaceuticals' higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Seagen.

Profitability

This table compares Alnylam Pharmaceuticals and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
Seagen-25.17%-18.32%-15.49%

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and Seagen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million66.32$-886,120,000.00($8.11)-15.47
Seagen$916.71 million32.54$-158,650,000.00($1.33)-124.40

Seagen has higher revenue and earnings than Alnylam Pharmaceuticals. Seagen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.0% of Seagen shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 31.1% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Seagen beats Alnylam Pharmaceuticals on 10 of the 15 factors compared between the two stocks.


Alnylam Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$220.31-0.1%$128.26 billion$23.36 billion17.77Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$59.50-1.3%$74.58 billion$22.45 billion61.34Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$218.10-0.7%$56.71 billion$4.16 billion27.54
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$508.31-0.4%$54.24 billion$7.86 billion19.68
Biogen logo
BIIB
Biogen
2.0$241.75-0.3%$37.20 billion$14.38 billion8.00Analyst Revision
Seagen logo
SGEN
Seagen
1.4$165.45-0.5%$29.83 billion$916.71 million-109.57Insider Selling
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.1$122.93-0.1%$26.90 billion$4.99 billion28.72
Incyte logo
INCY
Incyte
1.7$81.16-0.5%$17.77 billion$2.16 billion-51.69
Exact Sciences logo
EXAS
Exact Sciences
1.6$115.87-1.2%$17.43 billion$876.29 million-52.43
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$78.15-0.2%$14.19 billion$1.70 billion17.88
Repligen logo
RGEN
Repligen
1.4$181.43-1.3%$9.55 billion$270.24 million312.82Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.12-0.7%$8.89 billion$788.10 million45.08Analyst Downgrade
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$50.24-0.4%$7.02 billion$1.12 billion104.67Insider Selling
Unusual Options Activity
Novavax logo
NVAX
Novavax
1.8$102.60-7.1%$6.53 billion$18.66 million-37.31
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.07-0.3%$6.00 billion$1.45 billion13.87
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$22.76-1.0%$5.93 billion$182.24 million-19.79
Exelixis logo
EXEL
Exelixis
1.9$18.73-1.7%$5.81 billion$967.78 million39.02Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$41.14-1.1%$5.56 billion$195.99 million257.13Analyst Report
Insider Selling
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$80.41-1.5%$4.26 billion$1.11 billion25.86
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.50-0.2%$3.81 billion$806.43 million-9.28
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$54.00-3.6%$3.74 billion$36.13 million-80.60
Alkermes logo
ALKS
Alkermes
1.3$18.43-0.3%$2.93 billion$1.17 billion-40.06
OPKO Health logo
OPK
OPKO Health
1.9$3.95-1.0%$2.65 billion$901.90 million-11.97
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.63-1.1%$1.86 billion$428.41 million16.86
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$111.94-1.2%$1.73 billionN/A-10.11Analyst Report
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$87.41-1.0%$1.41 billion$120.28 million-88.29
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$9.77-2.0%$1.38 billion$102.43 million-11.77
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$18.21-2.5%$1.37 billion$638.60 million-6.79
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.39-2.6%$1.23 billion$252 million-3.61Analyst Revision
Innoviva logo
INVA
Innoviva
1.1$10.56-2.2%$1.07 billion$261.02 million5.39
Codexis logo
CDXS
Codexis
1.1$17.86-0.2%$1.06 billion$68.46 million-51.03
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.30-0.8%$993.90 million$82.27 million-12.33
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$21.75-2.3%$860.58 million$3.57 million-9.75
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$4.76-2.1%$840.45 million$48.83 million-6.26Analyst Report
MannKind logo
MNKD
MannKind
0.9$2.95-3.7%$686.17 million$63.04 million-14.05
Agenus logo
AGEN
Agenus
1.6$3.51-4.0%$667.42 million$150.05 million-3.22
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.56-1.8%$665.40 million$109.33 million-3.74
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$12.11-1.9%$662.32 million$227.19 million5.79
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.44-0.0%$649.59 million$38.19 million37.47
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.92-1.0%$625.73 million$150,000.00-4.17
Geron logo
GERN
Geron
1.4$1.81-0.0%$561.95 million$460,000.00-5.17
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$2.93-0.3%$495.11 million$59.29 million-20.93
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75-0.0%$477.47 million$327.75 million-1.89
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.25-2.4%$468.24 million$35.22 million-3.10
Molecular Templates logo
MTEM
Molecular Templates
1.6$8.84-0.6%$441.68 million$22.27 million-4.33
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.44-1.1%$392.14 million$143.01 million-0.85
XOMA logo
XOMA
XOMA
1.4$32.66-0.5%$359.98 million$18.37 million-29.42Analyst Report
Insider Selling
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.56-2.3%$292.42 million$54.76 million-1.92
Verastem logo
VSTM
Verastem
1.5$1.70-7.1%$288.62 million$17.46 million-1.21
Fortress Biotech logo
FBIO
Fortress Biotech
1.7$2.61-3.4%$244.57 million$36.63 million-3.00
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.